ChemBridge, AstraZeneca Enter Chemistry Alliance

ChemBridge Corp. and ChemBridge Research Laboratories, Inc. (CRL) have entered into a multi-year chemistry discovery collaboration with AstraZeneca. Under the agreement ChemBridge and CRL scientists at Moscow and San Diego research sites will work with AZ scientists to develop highly advanced exclusive small molecule libraries enhancing AZ’s global drug discovery effort. Further details and financial terms were not disclosed.

“We are very pleased that after worldwide evaluation and due diligence AstraZeneca has selected ChemBridge and CRL as one of their chemistry partners,” said Eugene Vaisberg, chairman and chief executive officer of ChemBridge Corp. and CRL. “This new agreement serves as yet another confirmation of the excellent capabilities of CRL and ChemBridge in the expertise-driven area of small molecule research. We look forward to contributing our proven chemistry expertise to AstraZeneca’s global drug discovery program.”

Dr. Paul Leff, vice president of discovery enabling capabilities and sciences, AstraZeneca adds, “We chose to work with ChemBridge and CRL because of their reputation and abilities in drug discovery chemistry and library synthesis. I am confident that we will see promising outcomes resulting from this collaboration in the area of lead generation.”